---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-242643"
form_type: "8-K"
ticker: "OACC"
cik: "0002029769"
company_name: "Oaktree Acquisition Corp. III Life Sciences"
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:27:38.887227+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Oaktree Acquisition Corp. III Life Sciences appoints David A. Berry as independent director

## Summary
- Appointed Oct 17, 2025 as Class II director on audit, nominating, and compensation committees; deemed independent under Nasdaq and Rule 10A-3.
- Co-founder & Managing Partner of Averin Capital (since May 2025); former Partner/GP at Flagship Pioneering (2005-2025); founder/CEO of Valo Health.
- No cash compensation; eligible to invest non-controlling minority interest in Oaktree Acquisition Holdings III LS, consistent with other independent directors.
- Will execute standard Letter Agreement and Indemnity Agreement on same terms as directors/officers from IPO.

## SEC filing metadata
- accession: 0001193125-25-242643
- form_type: 8-K
- ticker: OACC
- cik: 0002029769
- company_name: Oaktree Acquisition Corp. III Life Sciences
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2029769/000119312525242643/0001193125-25-242643-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2029769/000119312525242643/d41718d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-242643
- JSON: https://secwatch.observer/filing/0001193125-25-242643.json
- Plain text: https://secwatch.observer/filing/0001193125-25-242643.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.